Down syndrome (DS) is the most prevalent genetic disease worldwide affecting about one in every 750 live births in all populations and is considered to be the most frequent etiology of intellectual disability ([@B1]-[@B4]). DS is caused by trisomy of whole or part of chromosome is accompanied with a large amount of health and social costs for patients and their families ([@B5]). It is coupled with many health issues, including mental retardation, congenital heart defects, gastrointestinal anomalies, audiovestibular and visual impairment, hematop-oietic disorders, early-onset Alzheimer disease and many other health problems ([@B1], [@B2], [@B6], [@B7]). While most fetal aneuplordy leads to miscarriage, trisomy 21 has the maximum survival rate. Due to the highest survival rate, the prenatal detection of fetal trisomy 21 is one of the commonest reasons for referral of women for prenatal diagnosis ([@B8], [@B9]). The incidence of births of children with DS rises with the age of the mother. Screening for DS is an important part of routine prenatal care. Prenatal diagnosis was presented in the 1970s with the major aim of detecting common aneuploidies such as trisomies 21, 18 and 13 ([@B7], [@B10]). Screening tests like the first trimester combination test are nowadays accessible to all pregnant women. Risk calculation is based on maternal age, nuchal translucency (NT) measurement by sonography and two serum markers: free beta hCG (free β-hCG) and pregnancy-associated plasma protein-A (PAPP-A). The test properties are rather good with a detection rate of almost 85-- 90% with a false-positive rate of 5--9% ([@B9], [@B11]).

Following a positive prenatal screening test, women are usually recommended to perform fetal karyotyping, which is considered as the gold standard to confirm the presence or absence of aneuploidies. Despite that, the main problem of karyotyping is the long period of time needed to achieve definitive results. Other faster and cheaper methods which have been introduced include interphase FISH and QF-PCR, but their main disadvantage is that they do not provide a full graphic demonstration of all chromosomes ([@B12]-[@B15]). Prenatal genetic diagnosis of DS and other aneuploidies is done using common cytogenetic tests or DNA analysis which needs fetal DNA to be obtained by invasive methods such as chorionic villus sampling (CVS) during the first trimester and amniocentesis during the second trimester ([@B16]-[@B18]). Even so, all these methods are invasive and associated with risk of fetal loss ([@B12], [@B19], [@B20]). Therefore, developing a reliable technique for noninvasive prenatal diagnosis (NIPD) of fetal trisomy 21 is very important ([@B8], [@B21], [@B22]).

Over the last few years, a great quantity of investigation have been accomplished on the development of noninvasive prenatal testing (NIPT) for fetal aneuploidies ([@B23], [@B24]). The discovery of cell free fetal DNA (cffDNA) in the maternal circulation has opened up a new horizon in the field of prenatal care and screening. Detection of chromosomal aneuploidy is a challenging goal in NIPD research ([@B22], [@B25]-[@B27]). Due to the high maternal DNA background and the nature of cffDNA in maternal plasma, determination of chromosomes dosage in the fetal genome is very difficult by common methods. To overcome these issues, background maternal DNA interference can be diminished by using molecular signatures present in maternal plasma but originating completely from fetus. The discovery of fetal-specific DNA methylation signatures in maternal blood offered an excellent opportunity to advent and improve new approaches for noninvasive screening testing. Genes that show differential DNA methylation between placental tissues and maternal blood cells have been used as fetal nucleic acid markers ([@B20], [@B28]-[@B31]). DNA methylation is a dynamic process and could change during development. It is believed that more than half of tissue differentially methylated regions (TDMRs) are methylated in embryonic tissues and during the differentiation, they undergo de-methylation process.These TDMRs have been used to enrich and assess fetal DNA ratio by using monoclonal antibody for methylated CpGs using MeDIP approach ([@B16], [@B18], [@B32], [@B33]).

The aim of this study was to evaluate and validate the methylated DNA immunoprecipitation of fetal DNA in maternal blood for diagnosis of fetal trisomy 21.

Materials and methods
=====================

**Sample collection and processing**

The samples included 40 pregnant women referred between October 2014 to December 2015 to the Medical Genetic Center of Genome (Iran, Isfahan). All pregnant women agreed to participate in the study and signed an informed consent. The study was approved by the Bioethics Committee of Isfahan University of Medical Sciences. The experimental procedure was followed as previously described with some modifications ([@B16], [@B33]). The participants were women with singleton pregnan-cies, between 13 and 21 weeks of gestation. All participants underwent invasive prenatal diagnosis by CVS or amniocentesis followed by FISH or chromosomal analysis. Briefly, for each pregnant woman 4 ml of peripheral blood was collected on EDTA and then aliquoted into four 1.5 ml tubes and stored at −80°C within 4 h of collection until further use.

**Extraction and fragmentation of DNA**

DNA was extracted from 400 l of peripheral blood sample via QIAamp DNA blood mini kit (QIAGEN) according to the manufacturer\'s instruction. Subsequently the DNA was quantified using a UV spectrophotometer at 260 and 280 nm and 5 g of the DNA was sheared by sonication at 100% power for 20 min using a WiseClean WUC Digital Ultrasonic (WUC-D06H) into fragment sizes of 100 to 500 bp. Verification of sheared DNA was done by electrophoresis on 1.5% agarose gel.

**MeDIP-real time qPCR**

Sonicated DNA was processed using the MeDIP methodology for immunoprecipitation of hypermethylated fragments (Diagenode's MagMeDIP kit) according to the manufacturer's instruction. Finally, real-time qPCR was carried out on an input and immunoprecipitated fragments for the selected 7 differentially methylated regions (DMRs) on chromosome 21 and 2 control regions (hypermethylated region on chromosome 13 and hypomethylated region on chromosome 22) as described previously ([@B33]). The real- time PCR was performed with specific primers ([Table 1](#T1){ref-type="table"}) and Maxima SYBR Green/ ROX qPCR Master Mix (Thermo Fisher Scientific) using StepOne Plus real-time PCR system (Applied Biosystems, USA). Amplification conditions were: first denaturation and enzyme activation at 95 C for 10 min, followed by 40 cycles of amplification at 95 C for 15 s and 60 C for 1 min. The reactions were performed in triplicate. Initially 6 maternal peripheral blood samples with known karyotype (normal pregnancies) were used to calculate the median for normalized □Ct. The ratio value for each of the DMRs was calculated using the median of normalized □Ct obtained from known samples. Finally, D value amount for each unknown sample was calculated using the following formula ([@B33]):

ΔCT^PB\ Normal^= CT^PBNormal\ Input^- CT^PBNormal\ IP^

ΔCT^PB\ T21^=CT^PBT21Input^- CT^PB\ T21IP^

Where IP correspond to Immunoprecipitated and PB represent the peripheral blood.

Norm ΔCT value ^PBNormal^= E^ΔCTPB\ Normal^

Norm ΔCT value ^PB\ T21^= E^ΔCTPB\ T21^

Where E= 10^\[-1/slope\]^ and Norm= Normalized

Ratio value ^sample;\ DMR^= Norm Δ^CTPB\ Sample(Normal\ or\ T21)^/Median (Norm ΔCT^PB\ Normal^)

D= -4.908+ 0.254 X~EP1~+ 0.409 X~EP4~+ 0.793 X~EP5~+ 0.324 X~EP6~+ 0.505 X~EP7~+ 0.508 X~EP9~+ 0.691 X~EP12~

where X~EPi~is fraction value for each EP marker ([@B33]).

###### 

Primers used for real-time PCR (16)

  Region                 Primer Name                  Sequence                      Amplicon size (bp)
  ---------------------- ---------------------------- ----------------------------- --------------------
  EP1                    ***EP1-F***                  5'-GCTGGACCAGAAAGTGTTGAG-3'   149
  ***EP1-R***            5'-GTGTGCTGCTTTGCAATGTG-3'                                 
  EP4                    ***EP4-F***                  5'-CTGTTGCATGAGAGCAGAGG-3'    95
  ***EP4-R***            5'-CGTCCCCCTCGCTACTATCT-3'                                 
  EP5                    ***EP5-F***                  5'-TGCAGGATATTTGGCAAGGT-3'    127
  ***EP5-R***            5'-CTGTGCCGGTAGAAATGGTT-3'                                 
  EP6                    ***EP6-F***                  5'-TGAATCAGTTCACCGACAGC-3'    104
  ***EP6-R***            5'-GAAACAACCTGGCCATTCTC-3'                                 
  EP7                    ***EP7-F***                  5'-CCGTTATATGGATGCCTTGG-3'    127
  ***EP7-R***            5'-AAACTGTTGGGCTGAACTGC-3'                                 
  EP9                    ***EP9-F***                  5'-GACCCAGACGATACCTGGAA-3'    110
  ***EP9-R***            5'-GCTGAACAAAACTCGGCTTC-3'                                 
  EP12                   ***EP12-F***                 5'-ATTCTCCACAGGGCAATGAG-3'    128
  ***EP12-R***           5'-TTATGTGGCCTTTCCTCCTG-3'                                 
  *HYP113*c              ***HYP113*** **c-F**         5'-CAGGAAAGTGAAGGGAGCTG-3'    79
  ***HYP113*** **c-R**   5'-CAAAACCCAATGGTCAATCC-3'                                 
  *U122*d                ***U122*** **d-F**           5'-AAGGTGCCCAATTCAAGGTA-3'    104
  ***U122*** **d-R**     5'-CTTCCCCACCAGTCTTGAAA-3'                                 

Results
=======

The ratio values obtained from the 7 selected DMRs ([Table 2](#T2){ref-type="table"}) were applied to the prediction equation for each sample separately to calculate the D value and determine their status (normal or trisomy 21) ([Tables 3](#T3){ref-type="table"} to 5). Cases that gave a D value above zero (cutting point) were classified as "trisomy 21" and below zero was classified as "normal". A total of 26 cases were classified as normal whereas the remaining 14 cases were classified as trisomy 21 ([Table 3](#T3){ref-type="table"}). The ratio values and D values obtained for normal and trisomy 21 samples were compared in [Table 4](#T4){ref-type="table"}. Statistical evaluation of the diagnostic efficiency of the discriminant analysis function, using this method showed a perfect classification for all normal and trisomy 21 cases resulting in a sensitivity and specificity of 100%. Karyotyping of the samples confirmed the above findings ([Table 2](#T2){ref-type="table"}).

Discussion
==========

The development of a NIPD technique for fetal trisomy 21 without carrying risk for the pregnancy is a promising research area in prenatal diagnosis ([@B21], [@B34]). The major challenge for the development of NIPD using cffDNA is the limited amount and fragmented structure of cffDNA in the maternal circulation. Over past few years, significant advances have been made for the enrichment and analysis of cffDNA. Nonetheless, most of these techniques are time consuming, laborious or difficult to implement on a large scale ([@B25], [@B34]). Currently, two methods have been developed and validated with almost 100% accuracy. The first method is based on next generation sequencing and the other one is based on MeDIP real-time qPCR. Several reports have shown that application of MeDIP in combination with real-time qPCR using maternal peripheral blood permits prenatal noninvasive detection of trisomy 21. Papageorgiou et al. in 2011 showed that the methylation ratio of normal and trisomy 21 cases for 12 selected DMRs could diagnose 14 trisomy 21 and 26 normal cases indicate 100% specificity and 100% sensitivity of the approach ([@B16]). Tsaliki*et*et al. in 2012 confirmed and evaluated this technique for noninvasive prenatal diagnosis of trisomy 21 in larger scale on 175 samples with 99.2% specificity and 100% sensitivity of the approach ([@B33]). In another study performed on 10 samples in 2013, Gorduza et al. showed that this approach could detect trisomy 21 cases with 100% specificity ([@B19]). The results of our research are in line with those of previous studies and corroborate the high sensitivity and specificity of this method for detection of trisomy 21.The main advantage of this method compared to the next generation sequencing technology is that, this approach could be accessible in all basic diagnostic laboratories as it requires no major and exclusive infrastructure, and is technically easier and less expensive. Moreover, this method will be able to offer results in less than 3 working days ([@B16]).

###### 

Ratio values obtained for 40 samples

  **Sample**   **Status**    **EP1**       **EP4**       **EP5**       **EP6**        **EP7**       **EP9**       **EP12**
  ------------ ------------- ------------- ------------- ------------- -------------- ------------- ------------- --------------
  1            TRISOMY       1.398713031   1.926523788   1.33403822    6.712266515    0.054477337   0.749292024   1.12537046
  2            TRISOMY       80.81213255   8.975547844   19.84770098   26.97591518    0.701687224   0.037296912   4.588110062
  3            NORMAL        3.140730166   0.377879982   1             0.020964613    2.487850856   1.845101267   1
  4            NORMAL        0.748775074   2.35169821    0.068878378   0.407612116    0.440901253   0.08029923    0.873795923
  5            TRISOMY       3.812401332   1.994462503   1.468354179   1              1.329422798   1             1.12654114
  6            NORMAL        0.000217214   0.000752408   0.000812978   0.00026385     0.000352914   0.000547636   0.000574424
  7            TRISOMY       0.930836701   4.597979392   0.992060493   11.53703023    0.311412768   1.003610869   0.164709994
  8            TRISOMY       2.186464614   1.486582984   1.929865094   21.499035      0.543706507   0.395349362   0.366021424
  9            TRISOMY       3.143997347   1.094293701   1.055919608   13.54041452    2.960621374   0.799516659   4.254530692
  10           TRISOMY       3.725928527   0.47467106    0.561944673   8.563496658    3.523233276   0.33662168    1.5888688
  11           TRISOMY       8.745858457   0.371645746   1.929865094   21.499035      0.135926627   0.395349362   0.366021424
  12           TRISOMY       2.156512383   1.829817797   2.526254524   5.095063052    2.545942789   0.730420924   2.047693801
  13           TRISOMY       8.773980448   1.145676711   1.480208083   28.44099435    10.39198969   3.655325801   1
  14           NORMAL        1.148300315   1             1.069102368   2.484232152    0.595387154   0.619810886   0.546957257
  15           NORMAL        0.000108882   0.000159179   9.11287E-05   1.59383E-05    0.000591521   0.037645925   0.03926866
  16           NORMAL        1             2.291194604   1.834898169   0.858208443    2.001386775   0.81966142    0.150235744
  17           NORMAL        0.329739814   1.918661226   0.224082207   1.151249077    0.00070436    0.008151041   0.162318574
  18           NORMAL        2.651116373   0.012242144   1.462564247   2.305692308    0.966539099   0.961394197   1.153485605
  19           TRISOMY       1.318228073   3.487032958   1.631840441   28.58526976    3.74223459    6.765516134   3.732131966
  20           NORMAL        2.740805592   2.07915887    1.158694309   1.247638519    1.094217853   1             0.668963777
  21           TRISOMY       7.318763871   6.480027789   1.054456807   17.16264495    1.841651394   0.78089474    1.519924856
  22           NORMAL        4.122730053   2.279946545   1.718917138   0.007584133    1.034475875   1             0.627201102
  23           NORMAL        2.04854559    0.496890547   0.201730342   2.553011436    0.559767643   0.697952132   1.435944511
  24           NORMAL        3.120116721   1.216722359   1.24444287    2.73435394     0.766788178   0.596750593   0.33844657
  25           TRISOMY       2.103220341   0.927873476   0.511746062   13.63459555    1.946523821   0.395349362   0.33844657
  26           NORMAL        0.758173533   1.598811661   0.76286517    0.748565259    2.709262157   0.027760936   0.398044049
  27           NORMAL        0.466710555   1.112650121   0.195264285   4.767391153    0.011437377   0.015126269   0.489031737
  28           NORMAL        0.570619122   0.812252396   1.858965505   1.971371945    0.990274229   0.525659321   0.947370071
  29           NORMAL        0.003987      0.399426      2.562408      0.014733       0.249636      0.689776      1.793776
  30           NORMAL        0.673896996   1.02313747    0.460253309   1.063780134    1.77509963    1.128338548   0.690158677
  31           NORMAL        0.54699517    0.498615626   0.341628443   3.021363992    2.208244625   1.72931418    0.914465089
  32           NORMAL        0.010803181   0.173378871   0.128647917   0.600484953    0.525550025   0.010958544   0.968618189
  33           NORMAL        0.375425877   0.734584317   0.101145217   0.462395736    0.698290863   0.008345418   0.004100456
  34           NORMAL        0.45081268    0.321078952   0.268036244   0.003491832    0.406098049   0.007229943   0.38315499
  35           NORMAL        1.306402992   2.177994031   0.464097554   0.665356752    2.946291143   0.198223512   0.542990928
  36           NORMAL        0.503687209   0.117358968   2.111839216   5.653718293    0.246883102   0.01382286    0.005727019
  37           NORMAL        2.587215093   0.018161158   0.426465222   0.002518534    0.021345859   0.64743174    0.005143621
  38           NORMAL        1.734355926   0.054598306   1.243580586   0.0000128382   0.007105244   1.690910149   0.0000690021
  39           NORMAL        2.636090682   0.063592481   0.531263683   0.012097058    0.00041262    0.058834247   0.039609766
  40           NORMAL        0.022411764   0.054296387   0.05390265    2.53818988     0.000628456   0.38151191    0.026571068
  **Mean**     4.003145281   1.449434464   1.445470785   5.988551466   1.319358826    0.796127543   0.91060985    
  **Median**   1.358470552   1.011568735   1.027228404   2.138532127   0.699989044    0.60828074    0.58707918    

###### 

The specification of samples

  ---------------------------------------------------------------------------------------------------------------------
  **Sample**   **Fetal Status**   **Prediction Value**\   **Gestational Weeks**   **Fetal Gender**   **Confirmed by**
                                  **(D-Value)**                                                      
  ------------ ------------------ ----------------------- ----------------------- ------------------ ------------------
  1            Trisomy            0.65367                 17                      Female             FISH

  2            Trisomy            47.31239                18                      Male               FISH

  3            Normal             -0.27123                16                      Female             Amniocentesis

  4            Normal             -2.70204                17                      Female             Amniocentesis

  5            Trisomy            0.322288                17                      Male               Amniocentesis

  6            Normal             -4.90605                16                      Female             Amniocentesis

  7            Trisomy            2.51462                 18                      Male               Amniocentesis

  8            Trisomy            5.479775                16                      Female             Amniocentesis

  9            Trisomy            6.403729                17                      Male               FISH

  10           Trisomy            2.500866                20                      Female             Amniocentesis 

  11           Trisomy            6.483923                16                      Female             Amniocentesis 

  12           Trisomy            3.113981                18                      Male               Amniocentesis 

  13           Trisomy            55.8825                 15                      Female             Amniocentesis 

  14           Normal             -1.56116                14                      Male               FISH

  15           Normal             -4.86127                18                      Female             Amniocentesis 

  16           Normal             -0.45287                16                      Male               Amniocentesis 

  17           Normal             -3.37215                21                      Female             Amniocentesis 

  18           Normal             -0.5492                 19                      Female             Amniocentesis 

  19           Trisomy            15.31432                16                      Male               Amniocentesis 

  20           Normal             -0.51555                16                      Female             Amniocentesis 

  21           Trisomy            8.37518                 15                      Male               Amniocentesis 

  22           Normal             -0.09896                16                      Female             Amniocentesis 

  23           Normal             -1.56781                16                      Male               Amniocentesis 

  24           Normal             -0.82083                16                      Female             Amniocentesis 

  25           Trisomy            2.24684                 15                      Female             Amniocentesis 

  26           Normal             -1.55669                16                      Male               Amniocentesis 

  27           Normal             -2.28352                14                      Female             Amniocentesis 

  28           Normal             -0.89621                18                      Male               Amniocentesis 

  29           Normal             -0.99089                15                      Female             Amniocentesis 

  30           Normal             -1.6622                 15                      Male               Amniocentesis 

  31           Normal             -0.68975                18                      Female             Amniocentesis 

  32           Normal             -3.59748                16                      Female             Amniocentesis 

  33           Normal             -3.92246                18                      Male               Amniocentesis 

  34           Normal             -3.97498                15                      Female             Amniocentesis 

  35           Normal             -1.13799                21                      Male               Amniocentesis 

  36           Normal             -1.08992                15                      Female             Amniocentesis 

  37           Normal             -3.56119                16                      Male               Amniocentesis 

  38           Normal             -2.59636                18                      Female             Amniocentesis 

  39           Normal             -3.72975                13                      Female             CVS

  40           Normal             -3.8025                 17                      Male               Amniocentesis 

  Min          -4.90605           13                                                                 

  Max          55.88245615        21                                                                 

  MEAN         3.581176892        16.61904762                                                        

  MEDIAN       -1.57612           15.24471                                                           
  ---------------------------------------------------------------------------------------------------------------------

###### 

The comparison of ratio and D values obtained for normal and trisomy 21 samples

  **Normal**   **Trisomy 21**                                                                                  
  ------------ ---------------- ---------- ------------- ----------- ------------- ------------- ------------- -------------
  EP1          0.000109         4.12273    1.248103      0.748775    0.000108882   4.122730053   1.248102725   0.748775074
  EP4          0.000159         2.351698   0.858713      0.498616    0.000159179   2.35169821    0.858712697   0.498615626
  EP5          0.0000911        2.562408   0.796095      0.464098    9.11287E-05   2.562408      0.796095449   0.464097554
  EP6          0.0000128        5.653718   1.30727       0.748565    1.28382E-05   5.653718293   1.307270292   0.748565259
  EP7          0.000353         2.946291   0.842427      0.559768    0.000352914   2.946291143   0.842426773   0.559767643
  EP9          0.000548         1.845101   0.548169      0.525659    0.000547636   1.845101267   0.548168811   0.525659321
  EP12         0.000069         1.793776   0.526149      0.489032    6.90021E-05   1.793776      0.526148993   0.489031737
  D Value      -4.90605         -0.09896   -2.14400069   -2.370295   0.322288      55.88245615   14.18725183   5.186462

![Prediction values (D) derived from the application of the diagnostic formula v1.1 for 40 blind tested cases. The Y axis represents the prediction value D and the X axis shows samples](ijmcm-6-013-g001){#F1}

As different ethnic groups may have different DNA methylation patterns and this could influence MeDIP-qPCR results, the main purpose of the present research was to evaluate and assess an optimized condition for NIPD of fetal trisomy 21 using cffDNA in maternal blood in Iran. We found that our results were in accordance with previous studies and this method is usable for screening in Iran. Furthermore, many different studies will need to be implemented to support the introduction of a new diagnostic strategy into the clinical practice of prenatal diagnostic laboratories.

This approach has provided the opportunity for NIPD of fetal trisomy 21 into many diagnostic laboratories ([@B19], [@B35]). Although the present study is based on a small sample of participants and data from more samples will be of help, our results confirm that this technology could be effective for screening trisomy 21 in pregnant women and could be applied in clinical practice.
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